NOX-E36 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 49 | 全身性エリテマトーデス | 1 |
49. 全身性エリテマトーデス
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00976729 (ClinicalTrials.gov) | May 2009 | 11/9/2009 | NOX-E36 First-in-Human (FIH) Study | NOX-E36 - A Phase I, Double-Blind, Placebo Controlled, Single Intravenous and Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects | Chronic Inflammatory Diseases;Type 2 Diabetes Mellitus;Systemic Lupus Erythematosus | Drug: NOX-E36;Drug: Placebo | NOXXON Pharma AG | NULL | Completed | 18 Years | 60 Years | Both | 72 | Phase 1 | United Kingdom |